Down-regulation of lncRNA MALAT1 alleviates vascular lesion and vascular remodeling of rats with hypertension.


Journal

Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617

Informations de publication

Date de publication:
25 07 2019
Historique:
received: 31 05 2019
accepted: 16 07 2019
pubmed: 26 7 2019
medline: 10 6 2020
entrez: 26 7 2019
Statut: ppublish

Résumé

Recently, the effect of long non-coding RNAs (lncRNAs) in hypertension (HTN) has been identified. This study aims to explore the expression of lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in HTN and its role in vascular lesion and remodeling of HTN rats. LncRNA MALAT1 expression was up-regulated in HTN patients, and lncRNA MALAT1 could be an effective index of HTN diagnosis. Down-regulated MALAT1 and inhibited Notch-1 could reduce relative factor expression, including inflammation-related factors, endothelial function-related factors and oxidative stress-related factors, and inhibit apoptosis of aortic endothelial cells of HTN rats. LncRNA MALAT1 expression in HTN patients and healthy controls was detected by reverse transcription quantitative polymerase chain reaction (RT-qPCR). Angiotensin II (Ang II)-induced HTN rat models were injected with MALAT1-siRNA, empty lentivirus vector, Notch pathway inhibitor (DAPT) and dimethyl sulphoxide (DMSO) via caudal vein. After three-week treatment, changes of blood pressure, inflammatory factor levels, endothelial function-related factors, oxidative stress indices and apoptosis of vascular endothelial cells were determined by a series of assays. This study revealed that down-regulated lncRNA MALAT1 could alleviate the vascular lesion and remodeling of HTN rats, the mechanism may be related to the inhibited activation of Notch signaling pathway.

Identifiants

pubmed: 31343412
doi: 10.18632/aging.102113
pii: 102113
pmc: PMC6682528
doi:

Substances chimiques

MALAT1 long non-coding RNA, human 0
RNA, Long Noncoding 0
RNA, Small Interfering 0
Receptor, Notch1 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5192-5205

Références

Leukemia. 2014 May;28(5):1060-70
pubmed: 24170027
Clin Exp Hypertens. 2011;33(8):525-32
pubmed: 21958429
Lancet. 2014 Feb 15;383(9917):622-9
pubmed: 24210779
J Hypertens. 2014 Jan;32(1):3-15
pubmed: 24270181
J Am Soc Hypertens. 2013 Nov-Dec;7(6):420-5
pubmed: 23910010
Int J Cardiol. 2016 Jan 15;203:214-6
pubmed: 26512840
Cardiovasc Res. 2014 Jul 1;103(1):17-27
pubmed: 24667851
Cancer Res. 2015 Apr 1;75(7):1322-31
pubmed: 25600645
Biomed Pharmacother. 2014 Jun;68(5):557-64
pubmed: 24857172
Acta Physiol (Oxf). 2016 Sep;218(1):13-27
pubmed: 27124368
Biochem Biophys Res Commun. 2018 Jun 27;501(3):688-695
pubmed: 29758198
Sleep Disord. 2015;2015:769798
pubmed: 26064690
Biochem Pharmacol. 2018 Jun;152:94-103
pubmed: 29577871
Lupus. 2008 Jul;17(7):645-53
pubmed: 18625637
Hypertension. 2018 Jun;71(6):1269-1324
pubmed: 29133354
Clin Chem Lab Med. 2017 Jan 1;55(1):38-46
pubmed: 27362960
Biomed Pharmacother. 2016 Dec;84:666-673
pubmed: 27697639
Am J Pathol. 2015 Nov;185(11):3066-75
pubmed: 26358219
Exp Cell Res. 2018 May 15;366(2):161-171
pubmed: 29548748
Tumour Biol. 2016 Mar;37(3):4025-33
pubmed: 26482776
J Aging Health. 2012 Jun;24(4):696-710
pubmed: 22422758
Int J Clin Exp Pathol. 2015 Jun 01;8(6):6981-7
pubmed: 26261587
Clin Chim Acta. 2017 Feb;465:131-143
pubmed: 28007614
Circ Res. 2014 Apr 25;114(9):1389-97
pubmed: 24602777
Bioinformatics. 2013 Oct 15;29(20):2617-24
pubmed: 24002109
Eur Respir J. 2016 Oct;48(4):1137-1149
pubmed: 27471204
Oncol Rep. 2011 Nov;26(5):1295-303
pubmed: 21785827
Artif Cells Nanomed Biotechnol. 2018;46(sup1):798-805
pubmed: 29575939
J Cell Biochem. 2015 Nov;116(11):2517-27
pubmed: 25914224
Tumour Biol. 2015 Apr;36(4):2947-55
pubmed: 25480417
Semin Perinatol. 2010 Jun;34(3):183-7
pubmed: 20494733
Int Immunopharmacol. 2018 Feb;55:69-76
pubmed: 29227823

Auteurs

Yu-Zeng Xue (YZ)

Cardiology Department, Liaocheng People's Hospital, Liaocheng 252000, Shandong Province, PR.China.

Zhi-Juan Li (ZJ)

Cardiovascular Department, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, Henan Province, PR.China.

Wei-Tao Liu (WT)

Cardiology Department, Liaocheng People's Hospital, Liaocheng 252000, Shandong Province, PR.China.

Jin-Jiao Shan (JJ)

Cardiology Department, Liaocheng People's Hospital, Liaocheng 252000, Shandong Province, PR.China.

Lei Wang (L)

Cardiology Department, Liaocheng People's Hospital, Liaocheng 252000, Shandong Province, PR.China.

Qian Su (Q)

Cardiovascular Department, Minhang Hospital, Fudan University, Shanghai 201100, PR.China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH